Results 61 to 70 of about 33,952 (165)

Near pan-alphavirus neutralization by an antibody-nanobody bispecific. [PDF]

MAbs
Pletnev S, Gardner CL, Sutton MS, Zhang B, Callahan V, Green C, Morano NC, Bylund T, Dunagan MM, Tsybovsky Y, Goldman ER, Shapiro L, Burke CW, Fox JM, Roederer M, Kwong PD, Zhou T.   +16 more
europepmc   +1 more source

Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1. [PDF]

Front Immunol
Zettl I, Ellinger I, Zghaebi M, Jance S, Izewski V, Drescher A, Breiteneder H, Röck M, Tollinger M, Eckl-Dorna J, Tillib SV, Flicker S.   +11 more
europepmc   +1 more source

Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide-HLA complex. [PDF]

MAbs
Watkins-Yoon J, Lu WC, Petrunak EM, Tubo NJ, Halmos S, McConaughy W, Ciuffa R, Weber C, Friedensohn S, Justesen S, Skovgaard M, Rachel R, Goshert C, Liu L, Bobrowicz P, Molldrem JJ, Zha D.   +16 more
europepmc   +1 more source

Narrative review of research progress and future development of bispecific antibodies in lung cancer: opportunities and challenges. [PDF]

Transl Lung Cancer Res
Dai Y, Fei J.
europepmc   +1 more source

bispecific antibody

Citation: 'bispecific antibody' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12951 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
openaire   +1 more source

CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis. [PDF]

Front Oncol
Li MJ, Qiu L, Chen D, Li CY, He Y, Li YL, Cen YL, Ren SH, Yao H, Fan FY.   +9 more
europepmc   +1 more source

Bispecific ANXA2/CD147 CAR-T cell therapy for osteosarcoma. [PDF]

Oncogene
Tang HJ, Dai W, Xiao DT, Li HN, Xiong L, Yang MX, Liang JM, Zou Z, Mai L, Li SH, Liu SY, Feng WY, Lin YH, He ML, Zhan XL, Liu Y.   +15 more
europepmc   +1 more source

Claudin 18.2 Targeting: A Pan-Cancer Perspective. [PDF]

Clin Cancer Res
Nikanjam M, Pérez-Granado J, Gramling MW, Larvol B, Kurzrock R.   +4 more
europepmc   +1 more source

A view from the periphery: trial design, commercial competition, and the access gap in multiple myeloma. [PDF]

Oncologist
Baysal M, Akpınar S.
europepmc   +1 more source

Correction: Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1. [PDF]

Front Immunol
Zettl I, Ellinger I, Zghaebi M, Jance S, Izewski V, Drescher A, Breiteneder H, Röck M, Tollinger M, Eckl-Dorna J, Tillib SV, Flicker S.   +11 more
europepmc   +1 more source